Consensus Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
12.36 ^USD	0.00%		-9.05%	+19.77%

04-12	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
04-12	Sector Update: Health Care	MT

Evolution of the average Target Price on Nurix Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2919db2884e2e.LPSAyH8Au0Hr74dA3nunayxvIxJgg9LM93pyOJLBDjA.RLmypzBiiBennqoCrQz3Pn4FcEMQwLu_vxAqe_mWb2RGpearLDj0EKbf0g~f7e5271a1e7be6dbcb3bd7fc554cde9e

Analyst Recommendations on Nurix Therapeutics, Inc.

Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	04-12	MT
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	04-11	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	04-11	MT
Morgan Stanley Adjusts Nurix Therapeutics' Price Target to $10 From $9, Keeps Equalweight Rating	02-26	MT
HC Wainwright Cuts Nurix Therapeutics Price Target to $19 From $35, Maintains Buy Rating	02-20	MT
RBC Cuts Price Target on Nurix Therapeutics to $22 From $24, Keeps Outperform, Speculative Risk	02-16	MT
RBC Cuts Price Target on Nurix Therapeutics to $24 From $29, Keeps Outperform, Speculative Risk	11-02	MT
RBC Trims Price Target on Nurix Therapeutics to $29 From $30, Keeps Outperform, Speculative Risk	23-10-13	MT
HC Wainwright Adjusts Price Target on Nurix Therapeutics to $35 From $33, Keeps Buy Rating	23-09-08	MT
HC Wainwright Adjusts Nurix Therapeutics Price Target to $33 From $53, Maintains Buy Rating	23-07-24	MT
Morgan Stanley Adjusts Price Target on Nurix Therapeutics to $12 From $11, Maintains Equal-Weight Rating	23-07-17	MT
Barclays Initiates Nurix Therapeutics at Overweight With $20 Price Target	23-03-09	MT
Oppenheimer Initiates Coverage on Nurix Therapeutics With Outperform Rating, $25 Price Target	23-02-28	MT
Stifel Adjusts Price Target on Nurix Therapeutics to $31 From $37, Maintains Buy Rating	23-02-14	MT
JPMorgan Chase Adjusts Price Target on Nurix Therapeutics to $36 From $37, Maintains Overweight Rating	23-02-13	MT
Berenberg Bank Adjusts Nurix Therapeutics' Price Target to $30 From $48, Maintains Buy Rating	23-02-13	MT
Needham Trims Price Target on Nurix Therapeutics to $31 From $32, Maintains Buy Rating	23-02-10	MT
RBC Cuts Price Target on Nurix Therapeutics to $30 From $39, Maintains Outperform, Speculative Risk	23-02-10	MT
Morgan Stanley Starts Nurix Therapeutics at Equalweight with $11 Price Target	22-10-11	MT
HC Wainwright Trims Nurix Therapeutics' Price Target to $53 From $54, Maintains Buy Rating	22-10-07	MT
Needham Adjusts Nurix Therapeutics' Price Target to $32 from $38, Keeps Buy Rating	22-07-12	MT
HC Wainwright Adjusts Price Target on Nurix Therapeutics to $54 From $60, Reiterates Buy Rating	22-07-11	MT
Baird Adjusts Price Target on Nurix Therapeutics to $32 From $41, Keeps Outperform Rating	22-07-08	MT
JPMorgan Adjusts Price Target on Nurix Therapeutics to $37 From $46, Reiterates Overweight Rating	22-07-08	MT
Piper Sandler Adjusts Price Target on Nurix Therapeutics to $35 From $55, Reiterates Overweight Rating	22-06-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.36 USD

Average target price

25.09 USD

Spread / Average Target

+103.00%

High Price Target

35 USD

Spread / Highest target

+183.17%

Low Price Target

14 USD

Spread / Lowest Target

+13.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nurix Therapeutics, Inc.

Baird
RBC Capital Markets
Morgan Stanley
HC Wainwright
Barclays
Oppenheimer
Stifel Nicolaus
Berenberg Bank
JPMorgan Chase
Needham & Co.
Piper Sandler
Wells Fargo Securities
SVB Leerink
J.P. Morgan Chase

Ratings for Nurix Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar